Learning the effects of psychotropic drugs during pregnancy using real-world safety data: a paradigm shift toward modern pharmacovigilance
- 221 Downloads
The growing evidence on psychotropic drug safety in pregnancy has been possible thanks to the increasing availability of real-world data, i.e. data not collected in conventional randomised controlled trials. Use of these data is a key to establish psychotropic drug effects on foetal, child, and maternal health. Despite the inherent limitations and pitfalls of observational data, these can still be informative after a critical appraisal of the collective body of evidence has been done. By valuing real-world safety data, and making these a larger part of the regulatory decision-making process, we move toward a modern pregnancy pharmacovigilance. The recent uptake of real-world safety data by health authorities has set the basis for an important paradigm shift, which is integrating such data into drug labelling. The recent safety assessment of sodium valproate in pregnant and childbearing women is probably one of the first examples of modern pregnancy pharmacovigilance.
KeywordsPharmacovigilance Pregnancy Psychotropic drugs Real-world data Safety
AL’s postdoctoral research fellowship is funded through the HN’s ERC Starting Grant “DrugsInPregnancy”, ERC-STG-2014 under grant agreement No 639377.
Conflicts of interest
The authors declare that they have no conflict of interest.
- 3.Bakker MK, Kolling P, van den Berg PB, de Walle HE, de Jong van den Berg LT. Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands. Br J Clin Pharmacol. 2008;65(4):600–6. https://doi.org/10.1111/j.1365-2125.2007.03048.x.CrossRefPubMedGoogle Scholar
- 5.Pernia S, DeMaagd G. The new pregnancy and lactation labeling rule. Pharm Ther. 2016;41(11):713–5.Google Scholar
- 7.Dreyer NA, Blackburn SCF, Mt-Isa S, Richardson JL, Thomas S, Laursen M, et al. Direct-to-patient research: piloting a new approach to understanding drug safety during pregnancy. JMIR Public Health Surveill. 2015;1(2):e22. https://doi.org/10.2196/publichealth.4939.CrossRefPubMedPubMedCentralGoogle Scholar
- 10.Kieler H, Artama M, Engeland A, Ericsson O, Furu K, Gissler M, et al. Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries. BMJ. 2012;344:d8012. https://doi.org/10.1136/bmj.d8012.CrossRefPubMedGoogle Scholar
- 13.Kurz X, Perez-Gutthann S. Strengthening standards, transparency, and collaboration to support medicine evaluation: ten years of the European network of centres for pharmacoepidemiology and pharmacovigilance (ENCePP). Pharmacoepidemiol Drug Saf. 2018. https://doi.org/10.1002/pds.4381.PubMedCentralCrossRefPubMedGoogle Scholar
- 14.Pharmacovigilance Risk Assessment Committee (PRAC). Assessment report. Substances related to valproate 2014. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Valproate_and_related_substances_31/Recommendation_provided_by_Pharmacovigilance_Risk_Assessment_Committee/WC500177352.pdf. Accessed 18 Jan 2018.
- 18.FDA. U.S. Food and Drug Administration. Drugs. Development and approval process. Development resources. Labeling. Pregnancy and lactation labeling final rule. 2015. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Labeling/ucm093307.htm. Accessed 28 May 2018.
- 19.Risk assessment of medicinal products on human reproduction and lactation: from data to labelling: European Medicines Agency 2008. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000982.jsp&mid=. Accessed 20 Jan 2018.
- 20.European Medicines Agency (EMA). Summary of the EMA public hearing on valproate in pregnancy 2017. http://www.ema.europa.eu/docs/en_GB/document_library/Other/2017/10/WC500236051.pdf. Accessed 20 Jan 2018.